HealthyPhase 1NCT07301203
Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects
A Phase 1 study testing CPD704 Inhalation Suspension in people with Healthy and Healthy Participants, run by Beijing Tide Pharmaceutical Co., Ltd at 1 site in China.
Trial summary
This is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension in healthy Chinese adult subjects. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy, Healthy Participants
- What is being tested?
- CPD704 Inhalation Suspension
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteChina
- Study dates
- 21 Oct 2025to 18 Jul 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- The subject can communicate well with the researchers, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent form;
- Healthy subjects aged 18-55 years (including the boundary value, subject to the time of signing the informed consent form), male or female;
- Body mass index (BMI) within the range of 19 ~ 28 kg/m2 (including the critical value), male weight ≥ 50 kg, female weight ≥ 45 kg;
- The subject has no plans to give birth, sperm or egg donation from the signing of the informed consent form to 90 days after medication, and voluntarily takes medically approved contraceptive measures (including his partner)
Who cannot join
- Patients who have taken any clinical trial drugs or participated in any drug clinical trial within 3 months before signing the ICF, or participated in other medical research activities, and are not suitable for participating in this trial as judged by the investigator;
- Previous or combined with the following diseases, cardiovascular disease [such as heart failure (such as fluid retention and edema), unstable ischemic heart disease, congestive heart failure poor control of coronary artery disease, myocardial infarction, long QT syndrome history, etc.], respiratory, renal, neurological, endocrine, immune, skin, gastrointestinal (such as gastrointestinal ulcers or gastrointestinal bleeding, etc.), liver or blood system and other diseases/abnormal history, the investigators judge that their participation in this trial may affect the safety of subjects or affect the analysis of study results;
- Patients with the following mental illness: 1) Uncontrolled/unstable major depressive disorder (MDD) or other serious mental disorders (such as schizophrenia, bipolar disorder or other serious mood or anxiety disorders) within 2 years before screening; 2) Suicide attempt or suicidal behavior 30 times before screening; 3) Suicidal ideation corresponding to Columbia-Suicide Severity Rating Scale (C-SSRS) category 4 or 5 in the past 30;
- Known hypersensitivity, immune reaction or intolerance to CPD704 Inhalation Suspension or any of the excipients in the drug product (polysorbate 80, sodium chloride, sodium citrate dihydrate, disodium edetate, sodium hydroxide or hydrochloric acid) and/or unsuitable for treatment with CPD704 Inhalation Suspension;
- Long-term oral drugs can not be stopped or suffering from gastric ulcer, gastritis affecting oral activated charcoal, or allergic to activated charcoal;
- Patients with severe infection, trauma or major surgery before signing the ICF, or planning to undergo surgery during the trial;
Show all 23Show fewer
- Use of any live vaccines (except influenza vaccine) within 28 days before signing the ICF or plan to receive vaccines during the study;
- Blood loss or blood donation of more than 400 mL within 3 months before signing the ICF (excluding female menstrual blood loss), or intend to donate blood during the trial or within 1 month after the end of the trial;
- Smokers or those who smoke more than 5 cigarettes per day within 3 months before signing the ICF, or those who cannot comply with the provisions of prohibiting smoking during the trial, or those who test positive for urine cotinine;
- Pulmonary ventilation function test Forced expiratory volume in the first second (FEV1) measured value/FEV1 predicted value ≤ 80% or forced vital capacity (FVC) ≤ 80% of predicted value or any other clinically significant abnormalities;
- Use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 28 days before signing the ICF; or use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before signing the ICF. If the half-life of concomitant drugs is increased, the required time interval should be at least 5 half-lives of the drug;
- Excessive consumption of tea, coffee or caffeinated beverages (an average of more than 8 cups per day, 250 mL per cup) within 6 months before signing the ICF;
- Consumption of any grapefruit, caffeine-containing beverages or foods (such as grapefruit juice, coffee, strong tea, chocolate, caffeine-containing carbonated beverages, cola, cocoa, etc.) within 48 hours before the first dose;
- Those who have special requirements for diet and cannot abide by the unified diet;
- Unwilling or unable to tolerate multiple venipuncture or difficult venous blood sampling or a history of fainting;
- Previous history of drug abuse/drug use, or drug abuse screening (including tetrahydrocannabinolic acid, morphine, ketamine, methamphetamine, benzodiazepine, cocaine) results were positive;
- Regular drinking within 6 months before signing the ICF [i.e., women drink more than 14 standard units of alcohol per week, men drink more than 21 standard units of alcohol per week (1 standard unit contains 14 g of alcohol, such as 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine)] or can not abstain from alcohol during the trial; or positive breath alcohol test;
- The results of physical examination, vital signs examination, ECG, laboratory tests (blood routine, blood biochemistry, coagulation function, thyroid function, urine routine, stool routine, etc.), chest X-ray, abdominal B ultrasound examination during the screening period are judged by the study doctor as abnormal and clinically significant;
- Abnormal ECG findings during the screening period, such as bradycardia or tachycardia (heart rate < 50 bpm or > 100 bpm), QTc prolongation (QTcF interval ≥ 450 ms in males and ≥ 470 ms in females, corrected according to Fridericia's formula), arrhythmia, etc., and clinically significant as judged by the investigator;
- Patients with positive results of any test of hepatitis B surface antigen (HbsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (Syphilis TP) and human immunodeficiency virus test (HIV-Ag/Ab) during the screening period;
- Pregnant or lactating women, or positive blood pregnancy test results;
- Unwilling or unable to correctly use the nebulizer according to the nebulizer instructions Inhalation of investigational drugs or nebulizer use training failed;
- Any other condition that, in the opinion of the investigator, would make participation in the study inappropriate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100020
Jintong Li, +8615300059186, gcpljt@189.cn
About this study
Official title: A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Single and Multiple Doses of CPD704 Inhalation Suspension in Healthy Chinese Adult Subjects.
This is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension in healthy Chinese adult subjects.
Read the detailed description
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension administered via nebulization in healthy Chinese adult subjects.
- Conditions
- Healthy, Healthy Participants
- Being tested
- CPD704 Inhalation Suspension, CPD704 placebo
- Keywords
- Phase I Study of CPD704 in Healthy Subjects, CPX201-I-01
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CPD704 Inhalation SuspensionDrug
This trial employs standard jet nebulizers (air-compression nebulizers) for oral inhalation administration。
CPD704 placeboOther
The placebo is administered via standard jet nebulizer (air-compression nebulizer) for oral inhalation
| Study group | Role | What they receive |
|---|---|---|
| SAD 0.5mg | Other | For SAD 0.5mg cohort will enroll 2 subjects who will receive CPD704 once. 0.5 mg per administration Receives: Drug: CPD704 Inhalation Suspension |
| SAD 1.5mg | Other | The SAD 1.5mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant.1.5 mg per administration. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| SAD 3mg | Other | This group will include exploratory studies onmetabolite identification, excretion pathways, and excretion quantification(conducted in Cycle 1) as well as anactivated charcoal gastrointestinal absorption blockade study(conducted in Cycle 2). A total of12 subjects will be enrolled (10:2 =CPD704 treatment group: placebo group), Each subject will receive a single 3 mg dose per cycle via oral inhalation. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| SAD 6mg | Other | The SAD 6mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,6 mg per administration. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| SAD 9mg | Other | The SAD 9mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,9 mg per administration. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| SAD 12mg | Other | The SAD 12mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,12 mg per administration.. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| MAD 1.5mg | Other | Each cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation.
Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses).1.5 mg per administration. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| MAD 3mg | Other | Each cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation.
Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses) . 3 mg per administration. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
| MAD 6mg | Other | Each cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation.
Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses). Each dose:6mg. Receives: Drug: CPD704 Inhalation Suspension; Other: CPD704 placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety outcomes
Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.
Measured: From the date of informed consent signature until Day 7 for SAD group(Day 14 for SAD 3mg group) and Day 11 for MAD Group.
Secondary outcomes (6)
Pharmacokinetic (PK) endpoints
Plasma concentrations of CPD704 following nebulization of CPD704 inhalation suspension
Measured: During the period starting 60 minutes before initial drug administration through to 48hours after first dose
Pharmacokinetic (PK) endpoints
Cmax of CPD704 following nebulized administration of CPD704 inhalation suspension
Measured: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
Time to reach peak plasma concentration (Tmax) of CPD704 following nebulized administration of CPD704 inhalation suspension
Measured: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
Area under the plasma concentration-time curve from time zero to time t (AUC0-t) of CPD704 following nebulized administration of CPD704 inhalation suspension
Measured: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
t1/2 of CPD704 after nebulization of CPD704 inhalation suspension
Measured: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
PK profile of CPD704 inhalation suspension following activated charcoal blockade (including AUC0-∞, AUC0-t, Cmax and other parameters)
Measured: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start21 Oct 2025
- Primary completion8 Jun 2026 (estimated)
- Study completion18 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07301203
- Sponsor's protocol ID
- CPX201-I-01
- Status last verified
- Sep 2025
- First submitted
- 19 Nov 2025
- Last updated
- 24 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Single and Multiple Doses of CPD704 Inhalation Suspension in Healthy Chinese Adult Subjects.
- ClinicalTrials.gov ID
- NCT07301203
- Acronym / sponsor ID
- CPX201-I-01
- Conditions
- Healthy, Healthy Participants
- Keywords
- Phase I Study of CPD704 in Healthy Subjects, CPX201-I-01
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Beijing Tide Pharmaceutical Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 21 Oct 2025 (actual)
- Primary completion
- 8 Jun 2026 (estimated)
- Study completion
- 18 Jul 2026 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension in healthy Chinese adult subjects.
Detailed description
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension administered via nebulization in healthy Chinese adult subjects.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 9
| Arm | Type | Receives |
|---|---|---|
| SAD 0.5mg | Other | Drug: CPD704 Inhalation SuspensionFor SAD 0.5mg cohort will enroll 2 subjects who will receive CPD704 once. 0.5 mg per administration |
| SAD 1.5mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboThe SAD 1.5mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant.1.5 mg per administration. |
| SAD 3mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboThis group will include exploratory studies onmetabolite identification, excretion pathways, and excretion quantification(conducted in Cycle 1) as well as anactivated charcoal gastrointestinal absorption blockade study(conducted in Cycle 2). A total of12 subjects will be enrolled (10:2 =CPD704 treatment group: placebo group), Each subject will receive a single 3 mg dose per cycle via oral inhalation. |
| SAD 6mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboThe SAD 6mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,6 mg per administration. |
| SAD 9mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboThe SAD 9mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,9 mg per administration. |
| SAD 12mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboThe SAD 12mg cohort plans to enroll 10 subjects with 8 subjects receiving CPD704 and 2 subjects receiving placebo, administered as a single dose per participant,12 mg per administration.. |
| MAD 1.5mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboEach cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation. Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses).1.5 mg per administration. |
| MAD 3mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboEach cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation. Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses) . 3 mg per administration. |
| MAD 6mg | Other | Drug: CPD704 Inhalation Suspension, Other: CPD704 placeboEach cohort is planned to enroll 12 subjects (10:2 = CPD704 treatment group : placebo group). The route of administration is oral inhalation. Based on SAD study results, the MAD cohort will receive QD or BID dosing, with a proposed 5-day consecutive dosing regimen (for BID dosing, only a morning dose will be administered on Day 5, totaling 9 doses). Each dose:6mg. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- The subject can communicate well with the researchers, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent form;
- Healthy subjects aged 18-55 years (including the boundary value, subject to the time of signing the informed consent form), male or female;
- Body mass index (BMI) within the range of 19 ~ 28 kg/m2 (including the critical value), male weight ≥ 50 kg, female weight ≥ 45 kg;
- The subject has no plans to give birth, sperm or egg donation from the signing of the informed consent form to 90 days after medication, and voluntarily takes medically approved contraceptive measures (including his partner)
Key exclusion criteria (23 listed)
- Patients who have taken any clinical trial drugs or participated in any drug clinical trial within 3 months before signing the ICF, or participated in other medical research activities, and are not suitable for participating in this trial as judged by the investigator;
- Previous or combined with the following diseases, cardiovascular disease [such as heart failure (such as fluid retention and edema), unstable ischemic heart disease, congestive heart failure poor control of coronary artery disease, myocardial infarction, long QT syndrome history, etc.], respiratory, renal, neurological, endocrine, immune, skin, gastrointestinal (such as gastrointestinal ulcers or gastrointestinal bleeding, etc.), liver or blood system and other diseases/abnormal history, the investigators judge that their participation in this trial may affect the safety of subjects or affect the analysis of study results;
- Patients with the following mental illness: 1) Uncontrolled/unstable major depressive disorder (MDD) or other serious mental disorders (such as schizophrenia, bipolar disorder or other serious mood or anxiety disorders) within 2 years before screening; 2) Suicide attempt or suicidal behavior 30 times before screening; 3) Suicidal ideation corresponding to Columbia-Suicide Severity Rating Scale (C-SSRS) category 4 or 5 in the past 30;
- Known hypersensitivity, immune reaction or intolerance to CPD704 Inhalation Suspension or any of the excipients in the drug product (polysorbate 80, sodium chloride, sodium citrate dihydrate, disodium edetate, sodium hydroxide or hydrochloric acid) and/or unsuitable for treatment with CPD704 Inhalation Suspension;
- Long-term oral drugs can not be stopped or suffering from gastric ulcer, gastritis affecting oral activated charcoal, or allergic to activated charcoal;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CPD704 Inhalation SuspensionThis trial employs standard jet nebulizers (air-compression nebulizers) for oral inhalation administration。 | Drug | MAD 1.5mg, MAD 3mg, MAD 6mg, SAD 0.5mg, SAD 1.5mg, SAD 12mg, SAD 3mg, SAD 6mg, SAD 9mg |
| CPD704 placeboThe placebo is administered via standard jet nebulizer (air-compression nebulizer) for oral inhalation | Other | MAD 1.5mg, MAD 3mg, MAD 6mg, SAD 1.5mg, SAD 12mg, SAD 3mg, SAD 6mg, SAD 9mg |
Primary outcome
Safety outcomes
Time frame: From the date of informed consent signature until Day 7 for SAD group(Day 14 for SAD 3mg group) and Day 11 for MAD Group.
Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0.
6 secondary outcomes
Pharmacokinetic (PK) endpoints
Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after first dose
Pharmacokinetic (PK) endpoints
Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Pharmacokinetic (PK) endpoints
Time frame: During the period starting 60 minutes before initial drug administration through to 48hours after last dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CPD704 Inhalation Suspension in people with Healthy and Healthy Participants, run by Beijing Tide Pharmaceutical Co., Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yanru Yanru (+8618210654987, yanru.yan@cplabpharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety outcomes (time frame: From the date of informed consent signature until Day 7 for SAD group(Day 14 for SAD 3mg group) and Day 11 for MAD Group.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.